Pharmacogenomics & Personalized Medicine: Where Are We Now & Where Are We Going?
|
|
- Gerald Marsh
- 5 years ago
- Views:
Transcription
1 Pharmacogenomics & Personalized Medicine: Where Are We Now & Where Are We Going? Rif S. El-Mallakh, MD Professor and Director Mood Disorders Research Program Department of Psychiatry and Behavioral Sciences University of Louisville School of Medicine Louisville, Kentucky Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO Editor-in-chief Schizophrenia Research and Current Psychiatry Otsuka Pharmaceutical Development & Commercialization, Inc Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC. July 2017 MRC2.CORP.D advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
2 Speaker Profiles Rif El-Mallakh, MD Position: Dr. El-Mallakh is Professor and Director of the Mood Disorders Research Program in the Department of Psychiatry and Behavioral Sciences at the University of Louisville School of Medicine in Louisville, Kentucky. For the past 25 years, Dr. El-Mallakh has focused his research on the pathophysiology of bipolar illness. Dr. El-Mallakh has authored or coauthored over 250 peer-reviewed articles and 2 books. Education: Dr. El-Mallakh received his MD degree from the University of Illinois. He completed a medical internship and an adult psychiatry residency at the University of Connecticut. He spent 3 years as a clinical research fellow at the National Institute of Mental Health (NIMH) and joined the faculty of the Department of Psychiatry at the University of Louisville in Henry A. Nasrallah, MD Position: Dr. Nasrallah is the Sydney W. Souers Professor and Chair of the Department of Psychiatry and Behavioral Neuroscience at Saint Louis University (St. Louis, MO), and he is the Editor-in-Chief of Schizophrenia Research and Current Psychiatry. Education: Dr. Nasrallah earned his MD degree from the American University of Beirut, School of Medicine (Beirut, Lebanon). He completed a psychiatry residency at the University of Rochester Medical Center (Rochester, NY) and a neuroscience research fellowship at the National Institutes of Health (National Institute of Mental Health) Laboratory of Clinical Psychopharmacology (Washington, DC). 2
3 This program was developed with the support of Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck, LLC. The speakers are compensated contractors of Otsuka Pharmaceutical Development & Commercialization, Inc. 3 advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
4 PsychU Virtual Forum Rules of Engagement: Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Lundbeck, LLC. have entered into collaboration with OPEN MINDS, to explore new ways of bringing/increasing awareness around serious mental illness. OPDC/Lundbeck s interaction with OPEN MINDS is through PsychU, an online, non-branded portal dedicated to providing information and resources on important disease state and care delivery topics related to mental illness. One of the methods employed for the sharing of information will be the hosting of virtual fora. Virtual fora conducted by OPDC/Lundbeck are based on the following parameters: When conducting medical dialogue, whether by presentation or debate, OPDC/Lundbeck and/or its paid consultants aim to provide the viewer with information that is accurate, not misleading, scientifically rigorous, and does not promote OPDC/Lundbeck products. No continuing medical education (CME) credits are available for any PsychU program. OPDC/Lundbeck and/or their paid consultants do not expect to be able to answer every question or comment during a PsychU Virtual Forum; however, they will do their best to address important topics and themes that arise. OPDC/Lundbeck and/or their paid consultants are not able to provide clinical advice or answer questions relating to specific patient s condition. Otsuka and Lundbeck employees and contractors should not participate in this program (e.g., submit questions or comments) unless they have received express approval to do so from Otsuka Legal Affairs. OPDC/Lundbeck operate in a highly regulated and scrutinized industry. Therefore, we may not be able to discuss every issue or topic that you are interested in, but we will do our best to communicate openly and directly. The lack of response to certain questions or comments should not be taken as an agreement with the view posed or an admission of any kind. February 2017 MRC2.CORP.X
5 Objectives Define precision medicine and its potential benefits in patient care Review the history and basics of pharmacogenetics and pharmacogenomics Discuss the role of biomarkers in precision medicine Explore current developments in the use of pharmacogenomics and precision medicine in the psychiatric clinic Address gaps in understanding and barriers to the successful implementation of precision medicine 5
6 Pharmacogenomics in Precision Medicine 6
7 Precision Medicine in Psychiatry Precision Medicine: proposes tailoring health care to the individual by integrating data from their genetic makeup, epigenetic modifications, other biomarkers, clinical symptoms, and environmental exposures Goal: combine early diagnosis, targeted therapies, and more accurate prediction of disease susceptibility to reduce morbidity and mortality of psychiatric conditions Environmental Factors Genetic Variability Two important tools of precision medicine are pharmacogenomics and biomarkers Precision Medicine Clinical Presentation Prendez-Alvarez S and Nemeroff CB. Neurosci Lett Oct 13. doi: /j.neulet [Epub ahead of print.] 7
8 Pharmacogenetics and Pharmacogenomics According to the Pharmacogenomics Knowledge Base (PharmGKB.org) 1 : Pharmacogenetics: how variation in a single gene influences an individual s response to a single drug Pharmacogenomics: how all genes influence an individual s response to drugs Both have the potential to identify patients genetically predisposed to not respond to therapy or to develop unacceptable toxicity 2 Much of the early work in pharmacogenetics has focused on the contribution of genetic variability to variations in drug metabolism 3 1. Pharmacogenomics Knowledge Base. PharmGKB FAQs. Accessed July 18, Evans WE and Johnson JA. Annu Rev Genomics Hum Genet. 2001;2: Johnson JA et al. Am J Pharmacogenomics. 2001;1:
9 The Cytochrome P450 (CYP450) Family of Enzymes CYP450s are an important class of enzymes that catalyze a wide variety of reactions 1 CYP450s are responsible for: Production and metabolism of Detoxification of food 2 Metabolism of foreign endogenous compounds 2 chemicals 2 Example: Metabolism of estrogens by CYP3A4 3 Example: CYP2D6 metabolizes plant alkaloids to less toxic compounds 4 Example: Drug metabolizing enzymes contribute to a series of chemical reactions that increase the water solubility of drugs, allowing for excretion 1 Genetic variability in CYP450 enzymes (polymorphisms) influence a patient s response to a particular drug 1 1. Brunton LL et al. Goodman and Gillman s The Pharmacological Basis of Therapeutics. 11 th edition (2006); McGraw-Hill. 2. Lynch T and Price A. Am Fam Physician. 2007;76: Guengerich FP. Chem Res Toxicol. 2017;30: Ingelman-Sundberg M. Pharmacogenomics J. 2005;5:
10 CYP450s and Drug Metabolism CYP450s are responsible for 96% of reactions involved in the metabolism of drugs (marketed and under development): 75% of those reactions are carried out by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 Enzymes responsible for drug metabolizing reactions FMO AKR MAO Other P450 subtype contribution to drug metabolizing reactions 3A5 other 3A4 1A2 P450 2D6 2C19 2C9 AKR, aldo-keto reductase; CYP, cytochrome P450; FMO, flavin-containing monooxygenase; MAO, monoamine oxidase. Rendic S and Guengerich FP. Chem Res Toxicol. 2015;28:
11 Drug Metabolism Phenotypes: Cytochrome P450s Poor Metabolizers Intermediate Metabolizers Nonfunctional genes 1 Greater risk of adverse effects 1 1 Functional and 1 nonfunctional 1 gene Increased risk of adverse effects 1 Phenotypes Extensive Metabolizers 2 Functional wild-type genes 1 Most common phenotype 1 Ultra-rapid Metabolizers Extra gene copies 1,2 Low response to drug 1,2 Potential risk of high levels of metabolites 2 1. El-Mallakh RS et al. Clin Lab Med. 2016;36: Ingelman-Sundberg M and Sim SC. Biochem Biophys Res Commun. 2010;396:
12 Genetic Variability of Cytochrome P450 Drug Metabolism Certain polymorphisms of CYP450 can influence a patient s response to a particular drug 1 : There is large variation in the representation of different alleles in different ethnic populations, which can be viewed as a reflection of foods available for those populations 2,3 : The CYP2D6*17 allele, which shows altered substrate affinity, is the most common allele in black Africans, but is absent in Caucasian and Asian populations 3 The CYP2D6 intermediate metabolizer phenotype is nearly twice as prevalent in African Americans (~13%) than in Caucasians (7%) 4 Ethiopians have a higher frequency of gene duplication (resulting in ultra-rapid metabolism) of CYP2D6 (up to 29%) than the general population 5 51% of Asians have the CYP2D6*10 allele, which generates an unstable enzyme and contributes to an intermediate metabolizer phenotype, while only 1-2% of Caucasians have this allele 3 African Americans are 1.5- to 2.1-fold more likely to have only 1 functional copy of CYP2D6 (poor / intermediate metabolizer) and 1.4- to 3.4-fold higher to have 3 or more copies of CYP2D6 (ultra-rapid metabolizer) compared with other ethnicities 6 CYP, cytochrome P Lynch T and Price A. Am Fam Physician. 2007;76: Bousman CA et al. BMC Psychiatry, 2017;17: Ingelman-Sundberg M. Pharmacogenomics J. 2005;5: Clinical Pharmacogenetics Implementation Consortium. Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 update. and-cyp2c19/. Accessed July 18, Aklillu E et al. Pharmacogenetics. 2002;12: Beoris M et al. Pharmacogenet Genomics. 2016;26:
13 Drug Target and Pharmacogenomics Genetic variations related to disease susceptibility tend to be a much more powerful predictor of response compared with the CYP450 genotype Examples Serotonin transporter Variants associated with poorer response to antidepressants in MDD BDNF Polymorphism associated with more severe depressive illness Catechol-O-methyltransferase Variant associated with poor response to antidepressants Dopamine receptors Variants associated with schizophrenia and antipsychotic response BDNF, brain-derived neurotropic factor; CYP450, cytochrome 450; MDD, major depressive disorder. El-Mallakh RS. Clin Lab Med. 2016;36:
14 SERT: short vs long form A 44-base-pair deletion in the promoter region leads to decreased expression of SERT Normal Quantity of SERT transcription Wild-type promoter region SERT protein coding region transcription Reduced Quantity of SERT Short form promoter region SERT protein coding region SERT, serotonin transporter. Luddington NS et al. Prim Care Companion J Clin Psychiatry, 2009;11(3):
15 The Short-form SERT Allele Patients heterozygous or homozygous for the short-form SERT gene may have: An increased chance of developing depression following significant life adversity* 1 A decreased response to SSRI treatment 1 A slower response to SSRI treatment 2 : In a double-blind, placebo-controlled study in depressed patients aged 60 years (n = 176): Patients with 1 or 2 copies of the short-form allele had a significantly decreased response to an SSRI at week 1 (1.6% vs 16.7%) and week 2 (9.1% vs 34.6%) ǂ There was no difference in response between genotypes by week 8 Patients with bipolar disease who were homozygous for the short-form SERT were more likely to have a history of rapid cycling 1 : Short-form allele was associated with an increased risk of antidepressant-induced mania in patients with bipolar disease 1 Some evidence suggests that identifying the short-form allele in patients can be used to guide treatment decisions 1 *Demonstrated in multiple longitudinal studies. Response measured as Clinical Global Impression Scale - Improvement score of 2. ǂCompared with patients homozygous for the long-form allele. SERT, serotonin transporter; SSRI, selective serotonin reuptake inhibitor. 1. Luddington NS et al. Prim Care Companion J Clin Psychiatry, 2009;11(3): Durham LK et al. Psychopharmacology (Berl.). 2004;174:
16 DISCUSSION 16
17 Current Progress and Advances in Precision Psychiatry 17
18 Polling Question How often do you use pharmacogenomic testing to guide treatment decisions in your practice? A. Never B. Rarely C. Sometimes D. All the time 18
19 The Potential Impact of Pharmacogenetic Testing In a study that examined whether variations in metabolic capacity translate into clinically important parameters (predisposition to AEs or to be a nonresponder): Genotype was determined in patients at clinical extremes (ie, those with AEs or nonresponders): The poor metabolizer frequency in patients with AEs (n = 28) was 4-fold that of the country s population The ultra-rapid metabolizer frequency in nonresponders (n = 16) was ~5-fold that of the country s population Other studies have demonstrated an increased hospitalization rate in poor metabolizers treated with antidepressants and antipsychotics and an increase in the development of AEs * *Compared with extensive metabolizers. AE, adverse effect. Rau T et al. Clin Pharmacol Ther. 2004;75:
20 The Potential Impact of Pharmacogenomic Testing Gene-by-gene testing has shown limited clinical utility 1 In an analysis of 3 studies * utilizing combinatorial pharmacogenomic test results to inform medication changes for patients with treatment-resistant depression (N = 258), compared to unguided treatment, pharmacogenomic-guided treatment resulted in 2 : A 2.3-fold increase in the odds of clinical response (P = 0.004) A 53% greater improvement in depressive symptoms (P = ) A 1.7-fold relative improvement in response (P = 0.01) A NNT for 1 clinical response above that seen in the unguided group of 6.07 Phenotypes ascribed to any of the single genes failed to predict clinical outcomes Clinical utility analysis: medication decision congruent with testing guidance were reported to save significantly in medication costs 3 Proved especially effective at reducing costs in the primary care setting *8-10 weeks in duration. CYP, cytochrome P450; HRT2A, serotonin receptor 2A; NNT, number needed to treat; SLC6A4, serotonin transporter. 1. Benitez J et al. Appl Transl Genom. 2015,5: Altar CA et al. Mol Neuropsychiatry. 2015;1: Brown LC et al. Clin Ther. 2017;39: e1. 4. Hall-Flavin DK et al. Transl Psychiatry. 2012;2:e172. Genotype 4 CYP2D6, CYPC19, CYP1A2 HRT2A SLC6A4 algorithm Prescribing recommendations 20
21 Biomarkers in Precision Medicine Biomarker: a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives 1 While other medical fields utilize clinical examination in combination with biological tests and quantitative measurements, psychiatric diagnosis often relies solely on clinical examination 2 The FDA-NIH Biomarker Working Group divides biomarkers by clinical use into 7 classes 1 : Diagnostic Monitoring Pharmacodynamic / response Predictive Prognostic Safety Susceptibility / risk FDA, Food and Drug Administration; NIH, National Institutes of Health. 1. Food and Drug Administration-National Institutes of Health Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource Accessed July 18, Frye MA, Transl Psychiatry, 2015;5:e
22 Biomarkers in Psychiatry: Current Developments Beyond pharmacogenetics, there are no biomarkers qualified by the FDA for use in psychiatry 1,2 Examples of Biomarkers Under Investigation or In Use in the Psychiatric Clinic Class Diagnostic Monitoring Pharmacodynamic Predictive Prognostic Safety Susceptibility / risk 1. am/biomarkerqualificationprogram/ucm htm. Accessed July 18, Accessed July 18, Young JJ et al, Front Pscyhiatry. 2016;7: Woodruff DB et al. ADHD Atten Def Hyp Disord. 2011;3: Example in Psychiatry Increased blood levels of inflammatory markers (ie, CRP, IL-6, and TNFα) were significantly associated with atypical depression as compared to typical/melancholic depression 3 Measurement of cellular membrane potential may help diagnose ADHD 4 and bipolar disorder 5 Blood concentrations of an addictive drug can be used to monitor abstinence and compliance in patients prone to substance abuse 6 Serum BDNF levels are decreased in untreated MDD patients and treatment with antidepressant medications can restore these levels 7 REM latency was reported to predict response to treatment with certain antidepressants 7 Patients with MDD and high blood CRP levels corresponded to a better response to a TCA than an SSRI 8 Individuals with a copy of the short-form of the SERT promoter polymorphism exhibited more depression and suicidality in relation to stressful life events than did individuals homozygous for the long allele 7 In older patients ( 60 years) with MDD, lower evening cortisol levels predicted poorer course at 2 year follow-up 9 Currently in use: CYP2D6 poor metabolizers have higher than expected plasma concentrations of TCAs when given usual doses 2 Polymorphisms and variable number tandem repeat regions in the serotonin transporter gene were associated with development of MDD 7 BDNF, brain-derived neurotrophic factor; CRP, C-reactive protein; CYP, cytochrome p450; IL-6, interleukin 6; FDA, Food and Drug Administration; MDD, major depressive disorder; REM, rapid eye movements; SERT, serotonin transporter; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TNFα, tumor necrosis factor α. 5. Woodruff DV et al. Ann Clin Psychiatry. 2012;24(2): FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD) Prendez-Alvarez S et al. Neurosci Lett Oct 13. doi: /j.neulet [Epub ahead of print.] 8. Uher R et al. Am J Psychiatry. 2014;171: Kabia FM et al. Psychoneuroendocrinology. 2016;63:
23 Clinical Tools in Psychiatry Current clinical assessment of psychiatric disorders is predominantly restricted to evaluating mental and behavioral signs and symptoms 1 Physical Assessments Which Can Be Useful in Diagnosis of Psychiatric Conditions Presence of Cognitive Impairment Severe cognitive deficits across multiple domains are present in schizophrenia, bipolar disorder, and major depression 1 Test Batteries for memory, attention, visuospatial skills, and executive function can aid in diagnosis 1 Monitoring of cognitive impairment can be clinically useful, ie, in diagnosis, assessment of illness severity, and to monitor response to treatment 2 Presence of Neurological Soft Signs (NSS): One meta-analysis found that NSS scores decreased with remission of psychopathological symptoms of schizophrenia 3 This decrease is less pronounced in patients with non-remitting schizophrenia 3 Presence of Comorbidities: Physical illnesses can be markers for subsequent psychological disturbances 4 Mental health problems can be markers of later physical pathologies 4 1. Nasrallah HA. Curr Psychiatr. 2013;13: Nasrallah HA. Curr Psychiatr. 2008;7: Bachmann S et al. Front Psychiatry. 2014;5: Anisman H and Hayley S. J Psychiatry Neurosci. 2012;37:
24 DISCUSSION 24
25 Polling Question For those who answered never or rarely : What prevents you from implementing pharmacogenomic or biomarker testing? A. Reimbursement considerations B. Lack of sufficient knowledge C. Need for more clinical trial evidence D. Lack of standardization E. I currently use such testing in my practice 25
26 Barriers to Successful Implementation of Precision Medicine 26
27 Gaps in Understanding Difficulty interpreting how multiple genetic risk factors coalesce to affect disease risk 1 Heterogenous nature of most psychiatric disease 2 : Use of sophisticated clinical approaches to subdivide psychiatric syndromes into groups that exhibit a more homogenous response may aid in identification of pharmacogenomic targets for investigation 2 According to a survey of psychiatrists, ¾ of respondents agreed that genotyping results should be accompanied by psychoeducation such as genetic counseling 3 : There is a need for physician training on how to interpret and convey complex genetic results 4 Most tools have been developed based on Caucasian populations 5 : Design of tests can lead to false phenotyping in minority populations 5 Sparsity of data concerning clinical effectiveness: Few randomized controlled trials 6 Limited analysis of utility and cost effectiveness 5 1. Gandal MJ et al. Nat Neurosci. 2016;19: de Leon J. Acta Neuropsychiatr. 2014;26: Thompson C et al. Psychiatry Res. 2015;226: Perlis RH, World Psychiatry. 2016;15: Bousman CA et al. BMC Psychiatry. 2017;17: Luzum JA et al. Clin Pharmacol Ther Jan 16. doi: /cpt.630. [Epub ahead of print]. 27
28 Barriers to Implementation Lack of infrastructure and standardization 1 Clinician inexperience 1 Scarcity of clear and consistent recommendations for testing: As of mid-2017, the CPIC had published pharmacogenetic guidelines for 33 drugs, the majority of which relate to metabolism 2 : 12 guidelines have been released for drugs with psychiatric indications, 6 of which relate to metabolism of tricyclic antidepressants Lack of prospective randomized clinical trials for approach validation 1 Cost and reimbursement considerations 1 : Coverage is variable and reimbursement policies may change over time CPIC, Clinical Pharmacogenetics Implementation Consortium. 1. Luzum JA et al. Clin Pharmacol Ther Jan 16. doi: /cpt.630. [Epub ahead of print]. 2. Clinical Pharmacogenetics Implementation Consortium. Guidelines. Accessed July 18,
29 QUESTIONS 29
30 CLOSING 30
31 Upcoming Virtual Fora* Event Speaker(s) Date Time HEDIS Behavioral Health Measures: An Update From NCQA Junqing Liu, PhD, MSW Emily Morden, MSW Lauren Niles, MPH Tuesday, August 15, :00 pm 1:00 pm EST Suicide Affects Everyone: The Role of the Health Care Professional in Suicide Prevention Christine Moutier, MD Thursday, September 14, :00 pm 1:00 pm EST Innovations in The Criminal Justice System for Individuals with Mental Illness Lawrence G. Brown, JD Dean Barker Thursday, September 28, :00 pm 12:30 pm EST *Register for these programs at 31
32 Pharmacogenomics & Personalized Medicine: Where Are We Now & Where Are We Going? Rif S. El-Mallakh, MD Professor and Director Mood Disorders Research Program Department of Psychiatry and Behavioral Sciences University of Louisville School of Medicine Louisville, Kentucky Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO Editor-in-chief Schizophrenia Research and Current Psychiatry Otsuka Pharmaceutical Development & Commercialization, Inc Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC. July 2017 MRC2.CORP.D advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies
Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry, Saint Louis University,
More informationAntidepressant Utilization in Bipolar Disorder: What Is the Evidence?
Antidepressant Utilization in Bipolar Disorder: What Is the Evidence? 2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC March 2018 MRC2.CORP.D.00336 Today s
More informationBecome A Supporting Organization
Become A Supporting Organization 2018 Otuska Pharmaceutical Development & Commercialization, Inc. May 2018 MRC2.CORP.X.02619 Contents 1.0 Table Of Contents 1.1-1.7 PsychU Overview 1.1-1.2 Overview 1.3
More informationCo-Occurrence Of Substance Use Disorders With Mood Disorders & Psychosis
Co-Occurrence Of Substance Use Disorders With Mood Disorders & Psychosis Rebecca Roma, MD, MBA Medical Director of the Community Treatment Team Mercy Behavioral Health, Pittsburgh, PA Robert Nelson, MD
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationPharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
More informationLearn how you can support
Learn how you can support Sponsored by Otsuka Pharmaceutical Development and Commercialization, Otsuka America Pharmaceutical, Inc., Lundbeck, L.L.C. and Avanir Pharmaceuticals, Inc. 2016 Otsuka Pharmaceutical
More informationAn Update From NCQA : Focusing On HEDIS Behavioral Health Measures
An Update From NCQA : Focusing On HEDIS Behavioral Health Measures HEDIS = Healthcare Effectiveness Data & Information Set NCQA = National Committee For Quality Assurance 2018 Otsuka Pharmaceutical Development
More informationPsychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationTelepsychiatry: Enhancing Access to Mental Health Care
Telepsychiatry: Enhancing Access to Mental Health Care Jonathan Evans Chief Executive Officer Safe Harbor Behavioral Health and InnovaTel Telepsychiatry, LLC., Erie, PA Meera Narasimhan, MD Associate Provost
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: CP.PMN.68 Effective Date: 11.05.15 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationEvolving Psychiatry: Technology for Patient Care
Evolving Psychiatry: Technology for Patient Care David C. Mohr, PhD Director, Center for Behavioral Intervention Technologies Professor, Department of Preventive Medicine Northwestern University, Feinberg
More informationPsychiatry for the Non-Psychiatrist. January 19, 2019
Psychiatry for the Non-Psychiatrist January 19, 2019 Overview A large percentage of patients visiting non-psychiatric practices suffer from psychiatric conditions alone or complicating medical, surgical
More informationOpinions on the Treatment of MDD. Results of Surveys from the New York, North Carolina, and California PsychU Communities
Opinions on the Treatment of MDD Results of Surveys from the New York, North Carolina, and California PsychU Communities January 27 th, 2017 Otsuka Pharmaceutical Development & Commercialization, Inc.
More informationMeasurement-based Scales in Major Depressive Disorder:
This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka Pharmaceutical Development and Commercialization, Inc.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: NE.PMN.68 Effective Date: 01/01/2017 Last Review Date: Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationAmerican Psychiatric Nurses Association
Francis J. McMahon International Society of Psychiatric Genetics Johns Hopkins University School of Medicine Dept. of Psychiatry Human Genetics Branch, National Institute of Mental Health* * views expressed
More informationDecember 2014 MRC2.CORP.D.00011
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking
More informationClinical Policy Title: Pharmacogenomic tests for psychiatric medications
Clinical Policy Title: Pharmacogenomic tests for psychiatric medications Clinical Policy Number: 02.02.01 Effective Date: October 1, 2015 Initial Review Date: April 15, 2015 Most Recent Review Date: May
More informationAdherence in A Schizophrenia:
Understanding and Diagnosing Bipolar Disorder Treatment Promoting for Bipolar Treatment Disorder Adherence in A Schizophrenia: Resource for Providers Engagement Strategies for Health Care Providers, Case
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A
Local Coverage Determination (LCD): MolDX: GeneSight Assay for Refractory Depression (L36324) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor
More information2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC.
Neuromodulation Techniques: State of the Science Philip G. Janicak, MD Adjunct Professor Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine Consultant
More informationPsychiatric genomics 2018: what the clinician needs to know
Li_benefit VPA_benefit cbz_benefit Lam_benefit Combo_ms_benefit Olz_benefit Cloz_benefit Ris_benefit Quet_benefit Ari_benefit Zip_benefit Asen_benefit Luras_benefit Pali_benefit Fluphen_benefit Haldol_benefit
More informationExploring Nonpharmacological Anti-inflammatory Strategies in Mental Health: Connecting Science to Clinical Practice
Exploring Nonpharmacological Anti-inflammatory Strategies in Mental Health: Connecting Science to Clinical Practice Otsuka Pharmaceutical Development & Commercialization, Inc. Lundbeck, LLC 2017 Otsuka
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationClinical Policy Title: Pharmacogenomic tests for psychiatric medications
Clinical Policy Title: Pharmacogenomic tests for psychiatric medications Clinical Policy Number: 02.02.01 Effective Date: October 1, 2015 Initial Review Date: April 15, 2015 Most Recent Review Date: May
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationTreating Depression in Disadvantaged Women: What is the evidence?
Treating Depression in Disadvantaged Women: What is the evidence? Megan Dwight Johnson, MD MPH Associate Professor Medical Director, UWMC Inpatient Psychiatry Department of Psychiatry and Behavioral Sciences
More informationMemorandum. Claims Payment and Clinical Policy Clarification. Question/Issue:
Memorandum To: PerformCare Provider Network From: Scott Daubert PhD, VP Operations Date: August 1, 2015 Subject: PC-17 Pharmacogenomics tests for psychiatric medications Claims Payment and Clinical Policy
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationAdvanced Receptor Psychopharmacology
Advanced Receptor Psychopharmacology Otsuka Pharmaceutical Development & Commercialization, Inc. 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD February 2017 Lundbeck,
More informationUnderstanding and Addressing Medication Adherence in Psychiatry
Understanding and Addressing Medication Adherence in Psychiatry Dawn Velligan, PhD Director Division of Community Recovery, Research and Training Henry B. Dielmann Chair, Department of Psychiatry University
More information2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market
Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response
More informationNovember 2014 MRC2.CORP.X.00004
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid consultant of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking
More informationAn Introduction to Principles and Practice July 8, Presented by
An Introduction to Principles and Practice July 8, 2011 Presented by Biomarkers in Psychiatry Jay Lombard, DO Chief Scientific Officer and Medical Director Genomind 2 Our mission is to advance the care
More informationNew Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center
New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center Background Genetic testing Treatment options: Pharmacogenetics
More informationApplication of Pharmacogenetics Supplementary Worksheet
Application of Pharmacogenetics Supplementary Worksheet Section 1 Health Care Problem Section 2 Drug Metabolism Section 3 Phase I & II metabolism Section 4 Inhibitors and Inducers Section 5 DNA & Drug
More informationWhat s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry
What s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry New Depression Screening Guidelines US Preventive Services Task Force (USPSTF) updated its 2009 recommendations
More informationConsiderations in Managing Major Depressive Disorder in Patients With Comorbid Cardiovascular Disease
Considerations in Managing Major Depressive Disorder in Patients With Comorbid Cardiovascular Disease Otsuka Pharmaceutical Development & Commercialization, Inc. Lundbeck, LLC 2017 Otsuka Pharmaceutical
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationGenomind and The Genecept Assay
Genomind and The Genecept Assay A Growing Problem of Psychiatric Conditions One in four adults, approximately 61.5 M American adults suffer from mental illness 1 ; depression will become the largest health
More informationPharmacokinetics: The Basics
Pharmacokinetics: The Basics 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD January 2017 MRC2.CORP.D.00200 1 advice or professional diagnosis. Users seeking medical advice
More informationObjectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
More informationPharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.
Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationA Collaborative Approach To Care Coordination For Patients With Schizophrenia: Perspectives From Nursing & Social Work
A Collaborative Approach To Care Coordination For Patients With Schizophrenia: Perspectives From Nursing & Social Work Brooke Kempf PMHNP Psychiatric Mental Health Nurse Practitioner Hamilton Center, Inc.
More informationPsychiatric genomics 2016: what the clinician needs to know
Psychiatric genomics 2016: what the clinician needs to know Roy Perlis, MD MSc Center for Experimental Drugs and Diagnostics MGH Department of Psychiatry MGH Center for Human Genetic Research rperlis@partners.org
More informationJune 2015 MRC2.CORP.D.00030
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. June 2015 MRC2.CORP.D.00030 advice or professional
More informationPharmacogenomics: Assessment of Therapeutic Risk vs Benefit
Pharmacogenomics: Assessment of Therapeutic Risk vs Benefit Lawrence J. Lesko Clinical Professor Center for Pharmacometrics and Systems Pharmacology University of Florida at Lake Nona November 15, 2016
More information6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationWhite Paper. The Genes Analyzed by the Genecept Assay. May dynacare.ca
White Paper The Genes Analyzed by the Genecept Assay May 2017 888.988.1888 DynacareNext@dynacare.ca dynacare.ca GEN-WP003-v5-052017 INTRODUCTION Dynacare is pleased to present this summary of the genes
More informationSLCO1B1 Pharmacogenetic Competency
SLCO1B1 Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Which of the following is not currently a recognized SLCO1B1 phenotype? a) Low function b) Normal function c) Intermediate function
More informationNeurotransmitter Functioning In Major Depressive Disorder
Neurotransmitter Functioning In Major Depressive Disorder Otsuka Pharmaceutical Development & Commercialization, Inc. 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD January
More informationPrecision Medicine in Mental Health Care
Precision Medicine in Mental Health Care Study PI: David Oslin, MD 11/21/17 Background: Public Health Significance Depression is one of the world s great public health problems At least 1 in 7 Veterans
More informationMujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon
Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon State Hospital, Salem Oregon Assurex Health Inc. has
More informationPersonalized Medicine in Real Time
LABORATORY OF PERSONALIZED HEALTH LPH Personalized Medicine in Real Time DNA-Guided Clopidogrel (Plavix ) Management Pharmacogenetic Foundations and Case Study 1 Clopidogrel (Plavix ) Leading AntiPlatelet
More informationPSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development
THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Psychiatry Incidences of mental disorders such as depression, bipolar, anxiety disorders, and schizophrenia continue to grow around the
More informationUnderstanding The Role Of Neurotransmitters In The Treatment Of Depression
Understanding The Role Of Neurotransmitters In The Treatment Of Depression Robin Nelson, MD Psychiatrist DGR Behavioral Health, LLC Wyomissing, PA Prakash Masand, MD Chairman and CEO Global Medical Education
More informationWhite Paper. The Science Behind the Genecept Assay. January, 2016
White Paper The Science Behind the Genecept Assay January, 2016 Genomind, Inc. 2200 Renaissance Blvd Suite 100 King of Prussia, PA 19406 877.895.8658 www.genomind.com GEN WP003 v3 01182016 INTRODUCTION
More informationCurriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationTable of Contents. Preface Abstract Acknowledgements... 9
Table of Contents Preface... 5 Abstract... 7 Acknowledgements... 9 1. Introduction... 17 1.1 Bipolar Affective Disorder... 17 1.1.1 History and Symptomatology of Bipolar Disorder... 17 1.1.2 Pharmacotherapy...
More informationClinical Pharmacogenomics in Depression Treatment
Clinical Pharmacogenomics in Depression Treatment GORDON ANG, PHARMD PGY- 2 PSYCHIATRIC PHARMACY RESIDENT CENTRAL TEXAS VETERANS HEALTH CARE SYSTEM 1 Abbreviations CGI-S: Clinical Global Impression Severity
More informationThe WARFARIN Study: Genetic Testing and Systems Reengineering to Support Personalized Medicine
The WARFARIN Study: Genetic Testing and Systems Reengineering to Support Personalized Medicine Elizabeth O. Ofili, M.D., M.P.H., F.A.C.C. Professor of Medicine and Chief of Cardiology Associate Dean, Clinical
More informationCYP2D6: Genotypes, Phenotypes, and Genetic Testing
CYP2D6: Genotypes, Phenotypes, and Genetic Testing In 1975, several laboratory scientists at St. Mary s Hospital Medical School in London each ingested a 40 mg dose of debrisoquine, an antihypertensive
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Mental Health Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_mental_health_conditions 1/2014 6/2017 6/2018
More informationPharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik
Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationClinical Policy: Clomipramine (Anafranil) Reference Number: HIM.PA.149 Effective Date: Last Review Date: 05.18
Clinical Policy: (Anafranil) Reference Number: HIM.PA.149 Effective Date: 03.13.18 Last Review Date: 05.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationIS IT GENETIC? How do genes, environment and chance interact to specify a complex trait such as intelligence?
1 IS IT GENETIC? How do genes, environment and chance interact to specify a complex trait such as intelligence? Single-gene (monogenic) traits Phenotypic variation is typically discrete (often comparing
More informationGenetic Testing for Diagnosis and Management of Mental Health Conditions
Genetic Testing for Diagnosis and Management of Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationImproving Mental Health Care: A Case Study
Improving Mental Health Care: A Case Study Why Improve Mental Health Care? Because the prevalence and costs of mental health problems are increasing in America despite the high prescribing of psychotropic
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationIntroducing ValueOptions Clinical Care Alerts
Introducing ValueOptions Clinical Care Alerts January 2013 Agenda What are Clinical Care Alerts? How does it work? What are the benefits? Questions and Answers 2 The Issue of Poor Medication Adherence
More informationJonathan Haverkampf OCD OCD. Dr Jonathan Haverkampf, M.D.
Dr, M.D. Obsessive-Compulsive Disorders () can interfere significantly with a patient s life but has a reputation of being more difficult to treat. However, with a combination of psychotherapy and medication
More informationImplementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
More informationGenetic Influences on Response to Drug Treatment for Major Psychiatric Disorders
Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders Janusz K. Rybakowski Alessandro Serretti Editors Genetic Influences on Response to Drug Treatment for Major Psychiatric
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationGeneral Discussion 4
General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationRon van Schaik. Pharmacogenetics. London, Oct 8-9, Clinical implementation: a 7 year experience
Ron van Schaik Associate Professor Pharmacogenetics Eur Clin Chem / Advisor EMA - PGWG London, Oct 8-9, 2012 Pharmacogenetics Clinical implementation: a 7 year experience Pharmacogenetics Core Laboratory*
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationRisperidone Case 1: Drug-Drug Interactions
Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationThe Louis de la Parte Florida Mental Health Institute
Data Brief December 2003 Mary Rose Murrin, M.A. Kelley Dhont, M.S. David Thornton, M.A. The Louis de la Parte Florida Mental Health Institute Children s Psychotropic Medication Use by Age and Diagnostic
More informationCourse Title: 2012 Psychiatry CME To Go Audio Lecture Series
American Physician Institute for Advanced Professional Studies, LLC Course Title: 2012 Psychiatry CME To Go Audio Lecture Series Intended Audience: Psychiatrists CME Accreditation and Designation Statement
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationA Coding System to Measure Elements of Shared Decision Making During Psychiatric Visits
Measuring Shared Decision Making -- 1 A Coding System to Measure Elements of Shared Decision Making During Psychiatric Visits Michelle P. Salyers, Ph.D. 1481 W. 10 th Street Indianapolis, IN 46202 mpsalyer@iupui.edu
More informationCase Report 31-Year-Old Female Shows Marked Improvement in Depression, Agitation, and Panic Attacks after Genetic Testing Was Used to Inform Treatment
Case Reports in Psychiatry, Article ID 842349, 4 pages http://dx.doi.org/10.1155/2014/842349 Case Report 31-Year-Old Female Shows Marked Improvement in Depression, Agitation, and Panic Attacks after Genetic
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More information